Sequenom (SQNM) Falls After 'No News' On Re-Validation Of Down Syndrome Test

After rising over 20% yesterday, shares of Sequenom Inc. (Nasdaq: SQNM) are down 5.6% this AM. Yesterday, there was all types of speculation about the early release of the re-validation the company's SEQureDx Down syndrome test. The test was delayed in April due to mishandling of R&D test data and results.

With no news this morning, traders are selling yesterday's run-up.

Results of the re-validation of SEQureDx is not formally expected until the fourth quarter.

Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php

You May Also Be Interested In

• SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg
• Gossamer Bio raises up to $250M in private placement for PAH drug
• Alzamend Neuro fMRI data accepted for neuroscience conference poster